1. Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474:1823–36. https://doi.org/10.1042/BCJ20160510.

2. Barko PC, McMichael MA, Swanson KS, Williams DA. The gastrointestinal microbiome: a review. J Vet Intern Med. 2018;32:9–25. https://doi.org/10.1111/jvim.14875.

3. Sidhu M, Van der Poorten D. The gut microbiome. Aust Fam Physician. 2017;46:206–11.

4. • Arnold JW, Roach J, Azcarate-Peril MA. Emerging technologies for gut microbiome research. Trends Microbiol. 2016;24:887–901. https://doi.org/10.1016/j.tim.2016.06.008This paper highlights the recent advancements in quality and ease of gut microbiome analysis.

5. Ahmadmehrabi S, Tang WHW. Gut microbiome and its role in cardiovascular diseases. Curr Opin Cardiol. 2017;32:761. https://doi.org/10.1097/HCO.0000000000000445.

6. Cani PD. Human gut microbiome: hopes, threats and promises. Gut. 2018;67:1716–25. https://doi.org/10.1136/gutjnl-2018-316723.

7. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90:859–904. https://doi.org/10.1152/physrev.00045.2009.

8. Shabsigh R. Hypogonadism and erectile dysfunction: the role for testosterone therapy. Int J Impot Res. 2003;15:9–13. https://doi.org/10.1038/sj.ijir.3901030.

9. Buvat J, Bou JG. Significance of hypogonadism in erectile dysfunction. World J Urol. 2006;24:657–67. https://doi.org/10.1007/s00345-006-.

10. Ferrini MG, Gonzalez-Cadavid NF, Rajfer J. Aging related erectile dysfunction—potential mechanism to halt or delay its onset. Transl Androl Urol. 2017;6:20–7. https://doi.org/10.21037/tau.2016.11.18.

11. Althof SE. Quality of life and erectile dysfunction. Urology. 2002;59:803–10. https://doi.org/10.1016/S0090-4295(02)01606-0.

12. Cunningham GR. Testosterone and metabolic syndrome. Asian J Androl. 2015;17:192–6. https://doi.org/10.4103/1008-682X.148068.

13. Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract. 2014;68:314–29. https://doi.org/10.1111/ijcp.12319.

14. • Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14. https://doi.org/10.1371/journal.pbio.1002533The importance of this paper is that it provides an updated estimate of the number of microbes found in the gut. The sheer number alone is preliminary evidence that these microbes have an effect on multiple systems and functions of their host organism.

15. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;13:220–30. https://doi.org/10.1038/nature11550.

16. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. Science. 2005;10:1635–8. https://doi.org/10.1126/science.1110591.

17. Bull MJ, Plummer NT. Part 1: The Human human Gut gut Microbiome microbiome in Health health and Diseasedisease. Integr Med (Encinitas). 2014;13:17–22.

18. Björkstén B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol. 2001;108:516–20. https://doi.org/10.1067/mai.2001.118130.

19. LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol. 2013;24:160–8. https://doi.org/10.1016/j.copbio.2012.08.005.

20. Gallo A, Passaro G, Gasbarrini A, Landolfi R, Montalto M. Modulation of microbiota as treatment for intestinal inflammatory disorders: an uptodate. World J Gastroenterol. 2016;28:7186–202. https://doi.org/10.3748/wjg.v22.i32.7186.

21. Scheperjans F. Gut microbiota, 1013 new pieces in the Parkinson's Parkinson’s disease puzzle. Curr Opin Neurol. 2016;29:773–80. https://doi.org/10.1097/WCO.0000000000000389.

22. Hoeppli RE, Wu D, Cook L, Levings MK. The environment of regulatory T cell biology: cytokines, metabolites, and the microbiome. Front Immunol. 2015;6:61. https://doi.org/10.3389/fimmu.2015.00061.

23. Umu ÖCO, Rudi K, Diep DB. Modulation of the gut microbiota by prebiotic fibres and bacteriocins. Microb Ecol Health Dis. 2017;28. https://doi.org/10.1080/16512235.2017.1348886.

24. Smith M. PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569–73. https://doi.org/10.1126/science.1241165.

25. Dodd D, Spitzer MH, Van Treuren W, Merrill BD, Hryckowian AJ, Higginbottom SK, et al. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature. 2017;551:648–52. https://doi.org/10.1038/nature24661.

26. Bollrath J, Powrie F. Immunology. Feed your Tregs more fiber. Science. 2013;2:463–4. https://doi.org/10.1126/science.1242674.

27. Zhang LJ, Gallo RL. Antimicrobial peptides. Curr Biol. 2016;26:14–9. https://doi.org/10.1016/j.cub.2015.11.017.

28. Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;12:153–65. https://doi.org/10.1016/S0140-6736(12)60520-0.

29. • Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:423–32. https://doi.org/10.1016/j.juro.2018.03.115Low testosterone is a highly likely to be associated with gut microbiome dysbiosis. These updates guidelines are important in defining low testosterone.

30. El-Sakka AI. Prevalence of Peyronie’'s disease among patients with erectile dysfunction. Eur Urol. 2006;49:564–9. https://doi.org/10.1016/j.eururo.2005.10.026.

31. Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie’'s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;2011. https://doi.org/10.1155/2011/282503.

32. Humphries KH, Izadnegahdar M, Sedlak T, Saw J, Johnston N, Schenck-Gustafsson K, et al. Sex differences in cardiovascular disease - impact on care and outcomes. Front Neuroendocrinol. 2017;46:46–70. https://doi.org/10.1016/j.yfrne.2017.04.001.

33. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005;294:2996–3002. https://doi.org/10.1001/jama.294.23.2996.

34. Lane-Cordova AD, Kershaw K, Liu K, Herrington D, Lloyd-Jones DM. Association between cardiovascular health and endothelial function with future erectile dysfunction: the multi-ethnic study of atherosclerosis. Am J Hypertens. 2017;30:815–21. https://doi.org/10.1093/ajh/hpx060.

35. Banks E, Joshy G, Abhayaratna WP, Kritharides L, Macdonald PS, Korda RJ, et al. Erectile dysfunction severity as a risk marker for cardiovascular disease hospitalisation and all-cause mortality: a prospective cohort study. PLoS Med. 2013;10. https://doi.org/10.1371/journal.pmed.1001372.

36. Ponholzer A, Gutjahr G, Temml C, Madersbacher S. Is erectile dysfunction a predictor of cardiovascular events or stroke? A prospective study using a validated questionnaire. Int J Impot Res. 2010;22:25–9. https://doi.org/10.1038/ijir.2009.40.

37. Hotaling JM, Walsh TJ, Macleod LC, Heckbert S, Pocobelli G, Wessells H, et al. Erectile dysfunction is not independently associated with cardiovascular death: data from the vitamins and lifestyle (VITAL) study. J Sex Med. 2012;9:2104–10. https://doi.org/10.1111/j.1743-6109.2012.02826.

38. Mäkinen JI, Perheentupa A, Irjala K, Pöllänen P, Mäkinen J, Huhtaniemi I, et al. Endogenous testosterone and brachial artery endothelial function in middle-aged men with symptoms of late-onset hypogonadism. Aging Male. 2011;14:237–42. https://doi.org/10.3109/13685538.2011.593655.

39. Empen K, Lorbeer R, Dörr M, Haring R, Nauck M, Gläser S, et al. Association of testosterone levels with endothelial function in men: results from a population-based study. Arterioscler Thromb Vasc Biol. 2012;32:481–6. https://doi.org/10.1161/ATVBAHA.111.232876.

40. Akishita M, Hashimoto M, Ohike Y, Ogawa S, Iijima K, Eto M, et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res. 2007;30:1029–34. https://doi.org/10.1291/hypres.30.1029.

41. Corrigan FE, Al Mheid I, Eapen DJ, Hayek SS, Sher S, Martin GS, et al. Low testosterone in men predicts impaired arterial elasticity and microvascular function. Int J Cardiol. 2015;194:94–9. https://doi.org/10.1016/j.ijcard.2015.05.065.

42. Khazai B, Golden SH, Colangelo LA, Swerdloff R, Wang C, Honoris L, et al. Association of endogenous testosterone with subclinical atherosclerosis in men: the multi-ethnic study of atherosclerosis. Clin Endocrinol (Oxf). 2016;84:700–7. https://doi.org/10.1111/cen.12997.

43. Lai J, Ge Y, Shao Y, Xuan T, Xia S, Li M. Low serum testosterone level was associated with extensive coronary artery calcification in elderly male patients with stable coronary artery disease. Coron Artery Dis. 2015;26:437–41. https://doi.org/10.1097/MCA.0000000000000260.

44. Michos ED, Vaidya D, Gapstur SM, Schreiner PJ, Golden SH, Wong ND, et al. Sex hormones, sex hormone binding globulin, and abdominal aortic calcification in women and men in the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis. 2008;200:432–8. https://doi.org/10.1016/j.atherosclerosis.2007.12.032.

45. Yaron M, Greenman Y, Rosenfeld JB, Izkhakov E, Limor R, Osher E, et al. Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men. Eur J Endocrinol. 2009;160:839–46. https://doi.org/10.1530/EJE-09-0052.

46. Vlachopoulos C, Ioakeimidis N, Miner M, Aggelis A, Pietri P, Terentes-Printzios D, et al. Testosterone deficiency: a determinant of aortic stiffness in men. Atherosclerosis. 2014;233:278–83. https://doi.org/10.1016/j.atherosclerosis.2013.12.010.

47. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104:195–201. https://doi.org/10.1042/CS20020209.

48. Brand JS, den Ouden ME, Schuurmans MJ, Bots ML, van der Schouw YT. Endogenous sex hormones and subclinical atherosclerosis in middle-aged and older men. Int J Cardiol. 2013;168:574–6. https://doi.org/10.1016/j.ijcard.2013.01.242.

49. Vaidya D, Golden SH, Haq N, Heckbert SR, Liu K, Ouyang P. Association of sex hormones with carotid artery distensibility in men and postmenopausal women: multi-ethnic study of atherosclerosis. Hypertension. 2015;65:1020–5. https://doi.org/10.1161/HYPERTENSIONAHA.114.04826.

50. Dockery F, Bulpitt CJ, Donaldson M, Fernandez S, Rajkumar C. The relationship between androgens and arterial stiffness in older men. J Am Geriatr Soc. 2003;51:1627–32. https://doi.org/10.1046/j.1532-5415.2003.51515.x.

51. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644.

52. Bjekic MD, Vlajinac HD, Sipetic SB, Marinkovic JM. Risk factors for Peyronie's Peyronie’s disease: a case-control study. BJU Int. 2006;97:570–4. https://doi.org/10.1111/j.1464-410X.2006.05969.x.

53. Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie's Peyronie’s disease. J Urol. 2002;168:1075–9. https://doi.org/10.1097/01.ju.0000024040.55662.36.

54. La Pera G, Pescatori ES, Calabrese M, Boffini A, Colombo F, Andriani E, et al. Peyronie's Peyronie’s disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years. Eur Urol. 2001;40:525–30.

55. Carrieri MP, Serraino D, Palmiotto F, Nucci G, Sasso F. A case-control study on risk factors for Peyronie's Peyronie’s disease. J Clin Epidemiol. 1998;51:511–5. https://doi.org/10.1016/S0895-4356(98)00015-8.

56. Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J Am Coll Cardiol. 2013;62:697–703. https://doi.org/10.1016/j.jacc.2013.05.064.

57. Antonio L, Wu FC, O’'Neill TW, Pye SR, Carter EL, Finn JD, et al. Associations between sex steroids and the development of metabolic syndrome: a longitudinal study in European men. J Clin Endocrinol Metab. 2015;100:1396–404. https://doi.org/10.1210/jc.2014-4184.

58. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27:1036–41. https://doi.org/10.2337/diacare.27.5.1036.

59. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab. 2005;90:712–9. https://doi.org/10.1210/jc.2004-0970.

60. Chaudhary RK, Shamsi BH, Tan T, Chen HM, Xing JP. Study of the relationship between male erectile dysfunction and type 2 diabetes mellitus/metabolic syndrome and its components. J Int Med Res. 2016;44:735–41. https://doi.org/10.1177/0300060515623122.

61. Weinberg AE, Eisenberg M, Patel CJ, Chertow GM, Leppert JT. Diabetes severity, metabolic syndrome, and the risk of erectile dysfunction. J Sex Med. 2013;10:3102–9. https://doi.org/10.1111/jsm.12318.

62. Park JH, Cho IC, Kim YS, Kim SK, Min SK, Kye SS. Body mass index, waist-to-hip ratio, and metabolic syndrome as predictors of middle-aged men's men’s health. Korean J Urol. 2015;56:386–92. https://doi.org/10.4111/kju.2015.56.5.386.

63. Arrabal-Polo MÁ, Arias-Santiago S, López-Carmona Pintado F, Merino-Salas S, Lahoz-García C, Zuluaga-Gómez A, et al. Metabolic syndrome, hormone levels, and inflammation in patients with erectile dysfunction. ScientificWorldJournal. 2012. https://doi.org/10.1100/2012/272769.

64. El-Sakka AI, Tayeb KA. Peyronie's Peyronie’s disease in diabetic patients being screened for erectile dysfunction. J Urol. 2005;17:1026–30. https://doi.org/10.1097/01.ju.0000170231.51306.32.

65. Arafa M, Eid H, El-Badry A, Ezz-Eldine K, Shamloul R. The prevalence of Peyronie's Peyronie’s disease in diabetic patients with erectile dysfunction. Int J Impot Res. 2007;19:213–7. https://doi.org/10.1038/sj.ijir.3901518.

66. Kendirci M, Trost L, Sikka SC, Hellstrom WJ. Diabetes mellitus is associated with severe Peyronie's Peyronie’s disease. BJU Int. 2007;99:383–6. https://doi.org/10.1111/j.1464-410X.2007.06611.x.

67. Tefekli A, Kandirali E, Erol B, Tunc M, Kadioglu A. Peyronie's Peyronie’s disease: a silent consequence of diabetes mellitus. Asian J Androl. 2006;8:75–9. https://doi.org/10.1111/j.1745-7262.2006.00099.x.

68. McKelvey KJ, Ariyakumar G, McCracken SA. Inflammatory and immune system markers. Methods Mol Biol. 1710;2018:85–101. https://doi.org/10.1007/978-1-4939-7498-6_7.

69. Bocchio M, Desideri G, Scarpelli P, Necozione S, Properzi G, Spartera C, et al. Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage. J Urol. 2004;171:1601–4. https://doi.org/10.1097/01.ju.0000116325.06572.85.

70. Sullivan ME, Miller MA, Bell CR, Jagroop IA, Thompson CS, Khan MA, et al. Fibrinogen, lipoprotein (a) and lipids in patients with erectile dysfunction. A preliminary study. Int Angiol. 2001;20:195–9.

71. Billups KL, Kaiser DR, Kelly AS, Wetterling RA, Tsai MY, Hanson N, et al. Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Impot Res. 2003;15:231–6. https://doi.org/10.1038/sj.ijir.3901012.

72. Chiurlia E, D'Amico D’Amico R, Ratti C, Granata AR, Romagnoli R, Modena MG. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol. 2005;46(8):1503–6. https://doi.org/10.1016/j.jacc.2005.06.068.

73. Long T, Liu G, Wang Y, Chen Y, Zhang Y, Qin D. TNF-α, erectile dysfunction, and NADPH oxidase-mediated ROS generation in corpus cavernosum in high-fat diet/streptozotocin-induced diabetic rats. J Sex Med. 2012;9:1801–14. https://doi.org/10.1111/j.1743-6109.2012.02739.x.

74. Matos G, Hirotsu C, Alvarenga TA, Cintra F, Bittencourt L, Tufik S, et al. The association between TNF-α and erectile dysfunction complaints. Andrology. 2013;1:872–8. https://doi.org/10.1111/j.2047-2927.2013.00136.x.

75. Tremellen K, McPhee N, Pearce K. Metabolic endotoxaemia related inflammation is associated with hypogonadism in overweight men. Basic Clin Androl. 2017;27:5. https://doi.org/10.1186/s12610-017-0049-8.

76. Wickramatilake CM, Mohideen MR, Withanawasam BP, Pathirana C. Testosterone and high-sensitive C-reactive protein in coronary artery disease patients awaiting coronary artery bypass graft. Andrologia. 2015;47:493–8. https://doi.org/10.1111/and.12290.

77. Tsilidis KK, Rohrmann S, McGlynn KA, Nyante SJ, Lopez DS, Bradwin G, et al. Association between endogenous sex steroid hormones and inflammatory biomarkers in US men. Andrology. 2013;1:919–28. https://doi.org/10.1111/j.2047-2927.2013.00129.x.

78. Bobjer J, Katrinaki M, Tsatsanis C, Lundberg Giwercman Y, Giwercman A. Negative association between testosterone concentration and inflammatory markers in young men: a nested cross-sectional study. PLoS One. 2013;8. https://doi.org/10.1371/journal.pone.0061466.

79. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010;73:602–12. https://doi.org/10.1111/j.1365-2265.2010.03845.x.

80. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89:3313–8. https://doi.org/10.1210/jc.2003-031069.

81. Somers KD, Dawson DM. Fibrin deposition in Peyronie's Peyronie’s disease plaque. J Urol. 1997;157:311–5.

82. El-Sakka AI, Hassan MU, Nunes L, Bhatnagar RS, Yen TS, Lue TF. Histological and ultrastructural alterations in an animal model of Peyronie's Peyronie’s disease. Br J Urol 1998:Mar81:445-52.

83. Davis CJ Jr. The microscopic pathology of Peyronie's Peyronie’s disease. J Urol. 1997;157:282–4.

84. Vernet D, Nolazco G, Cantini L, Magee TR, Qian A, Rajfer J, et al. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease. Biol Reprod. 2005;73:1199–210. https://doi.org/10.1095/biolreprod.105.041038.

85. Halfvarson J, Brislawn CJ, Lamendella R, Vázquez-Baeza Y, Walters WA, Bramer LM, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017;2:17004. https://doi.org/10.1038/nmicrobiol.2017.4.

86. Yan Q, Gu Y, Li X, Yang W, Jia L, Chen C, et al. Alterations of the gut microbiome in hypertension. Front Cell Infect Microbiol. 2017;7:381. https://doi.org/10.3389/fcimb.2017.00381.

87. Richards EM, Pepine CJ, Raizada MK, Kim S. The gut, its microbiome, and hypertension. Curr Hypertens Rep. 2017;19:36. https://doi.org/10.1007/s11906-017-0734-1.

88. Jie Z, Xia H, Zhong SL, Feng Q, Li S, Liang S, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. 2017;8:845. https://doi.org/10.1038/s41467-017-00900-1.

89. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57–63. https://doi.org/10.1038/nature09922.

90. Li XS, Obeid S, Klingenberg R, Gencer B, Mach F, Räber L, et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J. 2017;38:814–24. https://doi.org/10.1093/eurheartj/ehw582.

91. Janeiro MH, Ramírez MJ, Milagro FI, Martínez JA, Solas M. Implication of trimethylamine N-Oxide oxide (TMAO) in disease: potential biomarker or new therapeutic target. Nutrients. 2018;10:1398. https://doi.org/10.3390/nu10101398.

92. Seldin MM, Meng Y, Qi H, Zhu W, Wang Z, Hazen SL, et al. Trimethylamine N-Oxide oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-κB. J Am Heart Assoc. 2016;5. https://doi.org/10.1161/JAHA.115.002767.

93. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575–84. https://doi.org/10.1056/NEJMoa1109400.

94. Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell. 2015;163:1585–95. https://doi.org/10.1016/j.cell.2015.11.055.

95. Gregory JC, Buffa JA, Org E, Wang Z, Levison BS, Zhu W, et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem. 2015;290:5647–60. https://doi.org/10.1074/jbc.M114.618249.

96. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341. https://doi.org/10.1126/science.1241214.

97. Liou AP, Paziuk M, Luevano JM Jr, Machineni S, Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013;5:178. https://doi.org/10.1126/scitranslmed.3005687.

98. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444:1022–3. https://doi.org/10.1038/4441022a.

99. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65:1331–40. https://doi.org/10.1161/HYPERTENSIONAHA.115.05315.

100. Nagpal R, Newman TM, Wang S, Jain S, Lovato JF, Yadav H. Obesity-linked gut microbiome dysbiosis associated with derangements in gut permeability and intestinal cellular homeostasis independent of diet. J Diabetes Res. 2018;2018. https://doi.org/10.1155/2018/3462092.

101. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913–6. https://doi.org/10.1053/j.gastro.2012.06.031.

102. Laakso M, Kuusisto J, Stančáková A, Kuulasmaa T, Pajukanta P, Lusis AJ, et al. The metabolic syndrome in men study: a resource for studies of metabolic and cardiovascular diseases. J Lipid Res. 2017;58:481–93. https://doi.org/10.1194/jlr.O072629.

103. Warshakoon HJ, Burns MR, David SA. Structure-activity relationships of antimicrobial and lipoteichoic acid-sequestering properties in polyamine sulfonamides. Antimicrob Agents Chemother. 2009;53:57–62. https://doi.org/10.1128/AAC.00812-08.

104. Huang ZY, Stabler T, Pei FX, Kraus VB. Both systemic and local lipopolysaccharide (LPS) burden are associated with knee OA severity and inflammation. Osteoarthritis Cartilage. 2016;24:1769–75. https://doi.org/10.1016/j.joca.2016.05.008.

105. Nicolucci AC, Hume MP, Martínez I, Mayengbam S, Walter J, Reimer RA. Prebiotics reduce body fat and alter intestinal microbiota in children who are overweight or with obesity. Gastroenterology. 2017;153:711–22. https://doi.org/10.1053/j.gastro.2017.05.055.

106. Morales P, Fujio S, Navarrete P, Ugalde JA, Magne F, Carrasco-Pozo C, et al. Impact of dietary lipids on colonic function and microbiota: an experimental approach involving orlistat-induced fat malabsorption in human volunteers. Clin Transl Gastroenterol. 2016;7. https://doi.org/10.1038/ctg.2016.20.

107. Benjamin JL, Hedin CR, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's Crohn’s disease. Gut. 2011;60:923–9. https://doi.org/10.1136/gut.2010.232025.

108. Lovat LB. Age related changes in gut physiology and nutritional status. Gut. 1996;38:306–9. https://doi.org/10.1136/gut.38.3.306.